Guidant's (nyse: GDT - news - people ) in-house-developed stent proved ineffective in March 2002, and trials were suspended.

FORBES: Magazine Article

For a while, it appeared that Indianapolis-based Guidant (nyse: GDT - news - people ) would get its own drug-coated stent to market before Boston Scientific.

FORBES: The Overachievers: Boston Scientific Has Heart

Medical-device maker Guidant (nyse: GDT - news - people ) was hit with a major blow today that could derail its efforts to co-market a drug-coated cardiac stent.

FORBES: Magazine Article

But that's where competitors also making the drug-coated stents, like Guidant (nyse: GDT - news - people )and Boston Scientific (nyse: BSX - news - people ), enter.

FORBES: Lawsuit Won't Hurt J&J, But Competition Might

Moroney likes HMO giant Cigna (nyse: CI - news - people ), medical products maker Guidant (nyse: GDT - news - people ) and medical imaging company Syncor International (nasdaq: SCOR - news - people ).

FORBES: Health Care Comeback?

But we now have a winner: Boston Scientific (nyse: BSX - news - people ) succeeded in convincing a federal judge to sideline rival Guidant's (nyse: GDT - news - people ) efforts to bring a drug-coated stent to market.

FORBES: Boston Scientific Wins Again

The stock market currently is focused on new stents being developed by Guidant (nyse: GDT - news - people ) and Medtronic (nyse: MDT - news - people ), but these stents are based on the same idea as those that are currently on the market: They are made of steel, coated with a polymer.

FORBES: The New Stent In Town